GIDE
28.3.2022 13:02:13 CEST | Business Wire | Press release
Several international digital specialists have praised the EU’s Digital Market Act , but say its primary aim is to foster competition among tech companies while trying to reign in some of the tech giants. They say its primary focus is not protecting the personal information of digital users.
“The Digital Market Act definitely places some constraints on how some of these tech giants can use consumers’ personal data, but in terms of giving them control over their own personal information, it comes up short,” said Dr Paul Twomey, one of the lead authors of a report entitled Empowering Digital Citizens .
The report, culminating two-years of work, was presented at the Global Solutions Summit in Berlin, Germany on 28 March 2022. The annual conference brings together senior government officials with top-level academic researchers, NGO leaders, and international CEOs. It transforms research-based insights into policy recommendations for the Group of Seven (G7) and Group of 20 (G20) inter-governmental forums.
“The buying and selling of personal data is part of a $515 billion (USD) market,” says Professor Dennis J. Snower, the report’s other lead author. “Digital users are simply not a part of this transactional system and in many cases don’t even know that it exists, nor do they know who has their personal information or how it is being used. We want humane market dynamics to apply to all participants in the online economy.”
Under the Empowering Digital Citizens proposal, online users would be given control over who has access to the personally identifiable information they create. They can also, with the help of a representative, set the terms under which their data can be used (according to the law), and in return they need to ensure that their data is accurate and verified by trusted third parties. “Only the illicit drug market and online data aggregators refer to people as users,“ says Twomey. “These proposals transform that model. They empower a world of digital citizens able to reinforce their democratic rights and counter the forces of disinformation.”
Twomey and Snower represent the Global Initiative for Digital Empowerment (GIDE), which is made up of over 70 specialists from around the world, including policy experts, researchers, Internet technical experts, business people, security specialists and others. GIDE is an initiative of THE NEW INSTITUTE. Based in Hamburg, THE NEW INSTITUTE is an institute of advanced studies and a platform to find answers to the most pressing ecological, economic and political challenges of our time.
The two digital researchers say a major problem is that many online users of “free services” are given artificially restricted choices of either revealing large amounts of personal data (by agreeing to the terms and conditions of digital services) or being excluded from the economic and social interactions that define modern life.
The Empowering Digital Citizens initiative will make online and digital consumers part of the economic model that is currently invisible to the average consumer.
Access the report here: Empowering Digital Citizens . Access an FAQ on the initiative here: Q&A on Human-Centered Digital Governance .
Membership of the Global Initiative for Digital Empowerment is on page four of the Empowering Digital Citizens report.
About Dr. Paul Twomey: Dr. Twomey is co-lead of the Global Initiative for Digital Empowerment and Fellow and Initiative Director for Digital Governance at THE NEW INSTITUTE. He is a Fellow and Core Theme Leader for “managing information and technology in the public interest” at the Global Solutions Initiative. Twomey is also a Distinguished Fellow at the Centre for International Governance Innovation and a Commissioner of the Global Commission for Internet Governance. He is the former CEO of ICANN, the global coordination body of the Internet’s addressing system.
About Prof. Dennis J. Snower : Prof. Snower is co-lead of the Global Initiative for Digital Empowerment and is the director for the Socio-Economic Transformation programme at THE NEW INSTITUTE.. He is founder and President of the Global Solutions Initiative; Professor of Macroeconomics and Sustainability at the Hertie School, Berlin; Senior Research Fellow at the Blavatnik School of Government, Oxford; and Non-resident Fellow of Brookings Institution. He is co-lead of this project. He is Research Fellow at the Centre for Economic Policy Research (London), at IZA (Institute for the Future of Work, Bonn), and CESifo (Munich).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220325005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
